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Abstract
Background: Viral capsid assembly involves the oligomerization of the capsid nucleoprotein (NP), which is an
essential step in viral replication and may represent a potential antiviral target. An in vitro transcription-translation
reaction using a wheat germ (WG) extract in combination with a sandwich ELISA assay has recently been used to
identify small molecules with antiviral activity against the rabies virus.
Results: Here, we examined the application of this system to viruses with capsids with a different structure, such
as the Rift Valley fever virus (RVFV), the etiological agent of a severe emerging infectious disease. The biochemical
and immunological characterization of the in vitro-generated RVFV NP assembly products enabled the distinction
between intermediately and highly ordered capsid structures. This distinction was used to establish a screening
method for the identification of potential antiviral drugs for RVFV countermeasures.
Conclusions: These results indicated that this unique analytical system, which combines nucleoprotein oligomerization
with the specific immune recognition of a highly ordered capsid structure, can be extended to various viral families and
used both to study the early stages of NP assembly and to assist in the identification of potential antiviral
drugs in a cost-efficient manner.
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Background
Bunyaviridae comprise the largest viral family with over
350 viral species in five genera [1, 2]. Many Bunyaviruses,
such as Rift Valley fever virus (RVFV), are significant
pathogens in humans, animals, and plants [3, 4]. RVFV
has recently been included in the WHO list of pathogens
potentially capable of causing major epidemics. Similarly,
as a prototype of emerging/re-emerging pathogens, RVFV
is classified as a Category A High-Priority Pathogen by the
NIH and is on the CDC select agent list [5]. Currently, no
licensed vaccine or therapeutics exist for use as medical
countermeasures against this potentially deadly disease of
humans and animals [6, 7].
The nucleoprotein (NP) capsid creates a protective
environment for the viral genome; therefore, the struc-
tural integrity of the capsid is essential for viral replica-
tion and the expression of viral genes. In the past,
wheat germ (WG) extract cell-free protein synthesis
(CFPS) of the viral NP alone has been shown to be suf-
ficient to recreate the assembly of spherical NPs [8].
Previous studies have shown similarity between CFPS-
produced highly ordered filamentous structures (HOFS)
of Hepatitis C virus (HCV) NPs and authentic viral NPs
in their biochemical properties [9–11]. More recently,
CFPS has been used to screen for small molecules that
block NP assembly of the rabies virus (RABV), which ex-
hibits a bullet-shaped morphology [12]. The compounds
identified have been tested and shown to be active against
the target viral family (Rhabdoviridae) in vivo.
The NPs within the Bunyaviridae family (which con-
sists of multiple 27 KDa chains) form a flexible filament-
ous ribonucleoprotein (RNP) complex with the tripartite
RNA genome of negative or ambisense polarity [13].
RVFV NPs assemble into a flexible serpentine-like struc-
ture [14], which is a stabilized multimeric form that fur-
ther assembles into hexameric rings when bound to
RVFV RNA [15]. Several studies have shown that NP
structural integrity is essential for the survival of the
RVFV [16–20].
In this report, the RVFV NP was generated by CFPS
and assembled into HOFS with biochemical and bio-
physical characteristics identical to those of the authen-
tic RVFV NPs. Furthermore, by modifying the CFPS
conditions and by applying a combined sucrose and
glycerol fractionation procedure, we were able to distin-
guish between HOFS and intermediately ordered assem-
bled structures (IOAS) of the filamentous RVFV NP
form. We found that the system can be used to deter-
mine the essential components for in vitro assembly and
to screen small molecules and cyclic peptides for activity
against RVFV NP formation, thus identifying the anti-
viral compounds that are active in an in vivo cell infec-
tion system. This approach has broad implications for
the study of other viruses with various capsid structures.
Results and Discussion
RVFV NP structures produced in the CFPS are similar in
size and buoyant density to authentic RVFV NP
Earlier studies of several viral families have demon-
strated the assembly of NP into high-molecular-weight
structures, by using WG CFPS directed by viral nucleo-
protein gene templates only. These studies, which did
not involve the addition of viral genomes or other struc-
tural proteins, sought to recreate a putative pathway of
HCV NP spherical assembly complexes. The structures
displayed a distinctive migration pattern in sucrose
density gradients and exhibited a striking similarity to
authentic viral HCV NP in terms of protease sensitivity,
buoyant density and electron microscopy appearance
[8, 10–12, 21]. However, these capsids were icosahe-
dral or bullet-shaped.
To address whether the assembly of NP high-order,
flexible filamentous structures could also be achieved in
this in vitro transcription-translation system, DNA en-
coding RVFV NP was transcribed and then translated
with a modified WG CFPS [12]. Newly synthesized
RVFV NP, in the presence of 35S-radiolabeled methio-
nine, was subjected to sucrose gradient sedimentation
and further detected by SDS-PAGE and autoradiog-
raphy (Fig. 1).
Interestingly, unlike the RABV NP, which sedimented
to the bottom of the sucrose gradient [12], and the HCV
NPs [8], which sedimented to the middle of the sucrose
gradient, the 27 kDa newly synthesized RVFV NP was
observed to sediment predominantly in the top and sec-
ond fractions of a sucrose step gradient (Fig. 1a, left
panel). As expected, the authentic RVFV NP comigrated
in these same fractions (Fig. 1a, right panel). We hypoth-
esized that the in vitro-generated product visualized on
the sucrose gradients in both the top and middle frac-
tions contains HOFS and IOAS, which cannot be distin-
guished by sucrose gradient sedimentation.
Detection of in vitro-generated putative RVFV NP flexible
filamentous assembly intermediates
To distinguish between RVFV NP HOFS and IOAS, the
CFPS-RVFV NPs at the top running fractions of the su-
crose gradients were further subjected to separation on
an additional glycerol density gradient to provide a
higher resolution of the different structures.
The separation of these two top sucrose gradient frac-
tions (Fig. 1a) on a glycerol gradient indeed generated
two distinct peaks (marked I and II in Fig. 1b), which
were further inspected by immunoprecipitation analysis
with an anti-RVFV NP monoclonal antibody (Additional
file 1: figure S1). This antibody, which recognizes only
the native structure of RVFV NPs, reacted only with the
bottom glycerol fraction, suggesting that this fraction
contains the RVFV NP HOFS and that the middle peak
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may represent putative intermediate steps in the assem-
bly process.
The intermediate structures were susceptible to pro-
teinase K digestion (Additional file 1: figure S1f and g
lanes 1 and 2), whereas the higher-order filamentous
structure RVFV NP that sedimented to the bottom of
the glycerol gradients was relatively resistant to PK
digestion (Additional file 1: figure S1f and g lane 3).
The separation of these two peaks required 16 h of
centrifugation (Additional file 2: figure S2b). Notably, a
higher proportion of the putative intermediate structures
was obtained by using a low amount of template DNA in
the CFPS compared with that obtained with a high
amount of template DNA (Additional file 3: figure S3).
The intermediate structures were also favored when the
reaction was performed at 26 °C rather than at 37 °C
(Additional file 4: figure S4a and S4b, respectively).
Interestingly, the glycerol gradient profile obtained with
the RVFV NPs generated with the CFPS (27 kDa) was
similar to those obtained with other HOFS NP viral
structures from phylogenetically related viral families
(HNTN and LASV) but different from those obtained
with spherical viral NPs (for example HCV) (Additional
file 5: figure S5).
Together, the data strongly suggest that the glycerol
gradient “peak I” (see Additional file 1: figure S1) indeed
represents an intermediate precursor structure of the
HOFS, which reproducibly sedimented in “peak II”. To
further confirm the presence of IOAS in the CFPS prod-
ucts, RVFV native NP structures generated in trans-
fected HEK 293 cells were also subjected to sucrose
gradient sedimentation followed by glycerol gradient
sedimentation, as described above. These native RVFV
NPs expressed in the HEK 293 cells sedimented at the
a
b
Fig. 1 Glycerol gradient characterization of the CFPS-generated RVFV NPs, collected from different fractions of the sucrose gradients. a Left upper
panel: SDS-PAGE analysis of the sucrose gradient fractions of radiolabeled RVFV NP translated in vitro. Right upper panel: western blot analysis of
the authentic RVFV NP. Middle panel: SDS-PAGE analysis of glycerol gradients, on which sucrose fraction 1 was analyzed. Lower panel: SDS-PAGE
analysis of glycerol gradients on which sucrose fraction 2 was analyzed. b Schematic representation of the two consecutive gradients used for
the analysis of the in vitro generated RVFV NP. Note that the upper sucrose gradient fractions generated two distinct peaks on the subsequent
glycerol gradient. These peaks are denoted I (middle peak) and II (bottom peak) and represent partial and higher-order assembly structures,
respectively (see below)
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top of the sucrose gradients, similar to the authentic
RVFV NPs and the CFPS-translated RVFV NPs. How-
ever, as expected, the separation of the top sucrose frac-
tion (Additional file 2: figure S2c, top panel) on
glycerol gradients (Additional file 2: figure S2c, bottom
panel) resulted only in the generation of the bottom
sedimentation peak and did not reveal the putative as-
sembly intermediates. These data also suggest that the
glycerol-gradient middle peak represents intermediate-
assembly structures. These intermediate structures
were absent in the transfected HEK 293 cultures due to
the large quantity of synthesized RVFV NP chains at
37 °C, which favored the generation of HOFS. Together,
the data strongly suggest that by combining sucrose
and glycerol gradients, it is possible to distinguish be-
tween HOFS and IOAS.
CFPS RVFV NP deletion mutants that do not assemble
into RVFV NP HOFS co-migrate with putative RVFV NP
IOAS on glycerol gradients
It has previously been demonstrated that RVFV NP
HOFS formation relies on the dimerization of RVFV NP
chains, which, in turn, depends on the integrity of the
NP [16]; accordingly, mutated forms of NP that exhibit
deletions are affected in their ability to assemble into
RVFV NP HOFS [19]. Sucrose density-gradient separa-
tions of the products encoded by RVFV NP N- or C-
terminal deletion mutants were carried out in the CFPS
under conditions that enabled the generation of both
RVFV NP IOAS and HOFS. When the top sucrose frac-
tions of these products were fractionated on glycerol
gradients, both N- and C-terminal deletion mutants of
RVFV NP preferentially sedimented to the middle frac-
tions (Additional file 2: figure S2e and 2f, respectively),
whereas the wt RVFV NP sedimented both at the middle
peak, representing the intermediate structures, and at the
bottom peak, suggesting the presence of RVFV NP HOFS
(Additional file 2: figure S2d). These results indicate that
the expression of RVFV NP mutants by CFPS mimics the
natural patterns of these oligomeric structures [20].
The lower-order assembly structures represent precursors
of the higher-order assembled NPs
To further demonstrate that the product sedimenting in
the glycerol-gradient middle fraction represented bona
fide intermediate structures, we conducted “chase” ex-
periments, which addressed whether these S35-labeled
RVFV NP IOAS could convert into HOFS after addition
of unlabeled IOAS. To perform these experiments, we
used assembly conditions that favored the synthesis of
35S labeled RVFV NP IOAS (26 °C for 10 min, see
above). The nonradiolabeled RVFV NP products (ob-
tained by conducting the in vitro reaction for 10 or
40 min at 26 °C) were then mixed with the radiolabeled
reaction and incubated for an additional 120 min (Fig. 2)
or 45 min (Additional file 6: figure S6). This reaction
product was analyzed on glycerol gradients. The data in-
dicated the transition of the radiolabeled IOAS to the
RVFV NP HOFS, as demonstrated by a shift of the la-
beled intermediate peak toward the bottom of the gly-
cerol gradient. This phenomenon was time-dependent
because the chase of the radiolabeled RVFV NP for only
45 min (rather than 120 min) did not result in a
complete transfer of the 35S into the RVFV NP HOFS
(Additional file 6: figure S6). The transition of the inter-
mediate fraction to the high-order assembly structures
was only partially promoted by a “chase” involving either
N- or C-terminal deleted versions of the RVFV NPs,
thus further substantiating the conclusion that the inter-
mediate fraction represents the precursor of the RVFV
NP HOFS (Fig 2c). Notably, when the reaction was both
initiated and chased with the deletion mutants, no
HOFS were detected. The assembly of the intermediates
into high-order NPs, as evidenced by the “chase” experi-
ments, was independent of ATP because the inhibition
of ATP by addition of Apyrase did not affect the accu-
mulation of the assembled structures (Additional file 7:
figure S7). Notably, this is not the case with other
in vitro virion assembly assays treated in the exact same
manner [12, 22, 23]. These observations strengthen the
idea that the low-order assembly structures represent
authentic intermediates, which possess the biophysical
characteristics necessary for their spontaneous transition
to fully assembled structures.
Converting the CFPS reaction to a moderate-throughput
plate screen
By analogy with the successful screens for RABV with a
bullet-like capsid shape [12], we adapted the assembly
assay characterized above to a moderate-throughput
screen that could be further scaled up into a high-
throughput screening method for the identification of
small molecules for blocking the RVFV NP assembly
pathway. A monoclonal antibody against the authentic
RVFV NP capsid was generated by USAMRIID, and
polyclonal pig and rabbit antibodies against various
RVFV NP peptides were generated (all available from
Prosetta Biosciences). CFPS RVFV NP was translated,
and an equal concentration of the labeled protein was
exposed to the various antibodies. The monoclonal anti-
body had a higher affinity than the other antibodies in
native IP conditions (Additional file 8: figure S8a). The
results indicated that protein G-purified coating mono-
clonal antibody provided the highest signal-to-noise ra-
tio at a dilution of 1:250 and the biotinylated detection
antibody was used at a final dilution of 1:126 (Additional
file 8: figure S8b). As predicted, using the monoclonal
antibody against RVFV NP for ELISA capture (Fig. 3b-I)
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and ELISA detection (Fig. 3b-IV), resulted in superior
sensitivity (a higher signal-to-noise ratio) than did use of
the polyclonal porcine or rabbit anti-RVFV NP anti-
bodies (Fig. 3a and Fig 3b-I). The synthesis was carried
out in a 384-well plate, in which a common translation
reaction mix was added to wells containing either 1 %
DMSO or small molecules at a concentration of 25 μM
dissolved in 1 % DMSO. At the end of the synthesis and
assembly reactions that resulted in the assembly of puta-
tive higher-structure filamentous RVFV NP as described
above, the reaction products were transferred to a sec-
ond 384-well plate precoated with the monoclonal anti-
body recognizing only the higher-structure RVFV NP
filamentous structures (see Additional file 1: figure S1d,
Additional file 8: figure S8a and the scheme illustrating
this process of selective detection in Fig. 3b-II and
Fig. 3b-III). The HOFS of the RVFV NP were evaluated by
coating the washed capture plate with the same biotinyl-
ated monoclonal antibody, which allowed the detection of
a fluorescence signal when incubated with streptavidin
HRP and a fluorogenic HRP substrate (Fig. 3b-IV). Small
molecules that inhibited the assembly were evaluated for
their inhibition of fluorescence, measured in relative fluor-
escence units (RFU). To avoid false positive signals, which
may be due to nonspecific inhibition of protein synthesis,
the mRNA for eGFP was added to the cell-free translation
reaction to enable the quantification of the overall protein
synthesis by fluorescence.
Over 10,000 compounds were screened, and a number
of “hits” were identified. These compounds demonstrated
inhibition of NP assembly in a dose-dependent manner




Fig. 2 Partial and full conversion of intermediate capsid structures into highly ordered capsids by nonradioactive CFPS-products. a Schematic
illustration of the chase experiments. b Glycerol-gradient fractionation profiles of the radioactive material generated by CFPS under conditions
favoring intermediate-assembly structures and “chased” by addition of the intermediate-assembly structures of nonradioactive products. As indicated:
dark blue, “mock” chase experiment (addition of buffer only); green, “chase” experiment (addition of nonradioactive intermediate structures). The chase
was performed for 120 min at 37 °C. c Glycerol-gradient fractionation profiles of the radioactive material generated by CFPS “chased” by the addition
of nonradioactive products involving N-terminal or C-terminal deleted NP forms. Red, reaction initiated with full-length NP forms and
chased with nonradioactive full-length forms (similar to panel B); light blue, reactions initiated with full-length forms and “chased” with
N-terminal deleted NP; red, reactions initiated with full-length forms and “chased” with C-terminal deleted NP; purple, reactions initiated and chased
with N-terminal deleted forms; yellow, reactions initiated and chased with C-terminal deleted forms
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activity against infectious RVFV in cell cultures (Fig. 4c).
The selected compounds, which promoted the inhibition
of NP assembly, were confirmed for their ability to pre-
vent the formation of the high-order assembled structures
generated by CFPS, as visualized by glycerol gradient sedi-
mentation (Fig. 5a).
The structures of compounds 6051 and 7007, which
had the lowest drug concentration (0.4 μM) that inhib-
ited 50 % of viral replication (EC50) in the yield reduc-
tion assay (Fig. 4c), are illustrated in Fig. 5c. No toxicity
was observed when the HEK cells were exposed for 24 h
to each of these compounds at a concentration of 1 μM
(Fig. 4d). Using a similar screen of small molecules
against LASV (to be discussed in greater detail else-
where), the same compounds were selected as “hits”
(Fig. 4b) and were validated as active against infectious
LASV in cell cultures (Fig. 4c). Interestingly, cyclic pep-
tides representing residues within the N- and C-terminal
regions of the RVFV NP were also found to be potent
inhibitors of assembly into HOFS (Fig. 6).
Conclusions
The biochemical characterization of RVFV NP CFPS
demonstrates the ability to form intermediate and
higher-structure filamentous RVFV NP within the same
in vitro translation reaction. Therefore, the exact
conditions that favor monomers over any oligomeric
filamentous structure and the methods to distinguish
these two are essential to the establishment of a high-
throughput screening system to identify small molecules
that interfere with RVFV NP assembly or that lead to
the disassembly of existing higher-structure filamentous
RVFV NPs or intermediates.
Our results validate the use of CFPS in combination
with sandwich ELISA assays based on specific mono-
clonal antibodies and provide a moderate-throughput
screening method for small molecules that block the
formation of RVFV NP containing structures that are
similar, if not identical, to RVFV NP HOFS.
We demonstrated that the anti-NP monoclonal anti-
body had a higher affinity for the native NP than the
denatured NP and a higher affinity for the HOFS
than the IOAS. Therefore, it is not surprising that the
specificity and sensitivity of the high-throughput
screening assay improved when a monoclonal anti-
body against the same epitope was used for capture
and detection, especially when the aim was to detect
the oligomerization of a single NP.
The power of this assay is substantiated by the obser-
vation that some of the compounds identified as hits
against RVFV NP oligomerization were validated as ro-
bustly active against infectious RVFV in cell culture. Our
a b
Fig. 3 HOFS are both preferentially captured and detected in the ELISA sandwich assay. a RVFV NPs derived from the top of the sucrose gradient
and the bottom of the glycerol gradient were preferentially detected by the anti-RVFV NP monoclonal antibody. b Diagram of the CFPS
in combination with the plate assay screening setup. I. The plates are initially coated with first Ab. II. Equal amounts of CFPS RVFV NP are
loaded onto each well. III. The plates are washed with PBS containing 1 % Triton X-100. IV. The fluorescently labeled anti-RVFV NP monoclonal antibody
detect only the RVFV NP oligomers
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data also strongly suggest that this method could be ex-
tended to other members of the viral family Bunyaviri-
dae and possibly to other viruses with higher-order
filamentous NP structures including LASV, a member of
the family Arenaviridae.
Notably, an established approach that has been used
to assemble putative spherical HCV NP and to identify
active compounds that have been validated against the
corresponding authentic viruses, can also be applied
with success to higher-structure filamentous viruses
such as the Bunyaviridae. Hence, a common set of
protein-protein interactions govern higher-structure fila-
mentous assembly across the viral family. However, this
study emphasizes the importance of a) identifying the
different biochemical conditions that apply to HOFS and
IOAS for each viral NP, b) establishing a set of anti-
bodies that distinguish between these two and c) using
the same monoclonal antibody as a capture and detec-
tion antibody for the high-throughput system.
The small molecules that were identified as potent
anti-RVFV and anti-LASV in this study, together with
the one that was identified as anti-RABV in a previous
study using the CFPS, have a common skeleton, namely
3,7-bis(dialkylamino)phenothiazine-5-ium derivatives.
These compounds have been shown to have various bio-
medical applications [24], and one of them, Methylene
Blue, has been demonstrated to abolish West Nile virus
infection in vivo, when photoinactivated [25]. Further
studies on the affinity of each structure for the various
viral NPs should be carried out.
Finally, the correlation between small-molecule
drugs that inhibit NP assembly and their ability to in-
hibit virus growth in the infectious virus inhibition
assay demonstrates that inhibition of NP assembly
can be used as a quick, accurate, reliable, and afford-
able assay method to screen for potential antiviral
drugs. This CFPS method is based on the synthesis of
the viral nucleoprotein at different NP assembly
stages. Thus, it could potentially be used to identify
drugs that inhibit NP assembly formation as well as
drugs that disassemble pre-existing NPs into their
intermediate structures, providing an important ad-
vantage for screening therapeutics. To our knowledge,
this is the first demonstration of a small molecule
that inhibits assembly of higher-order flexible fila-
mentous structures of RVFV NP.
a b
c d
Fig. 4 Inhibitory small molecules identified using the CFPS have an inhibitory effect in live virus assay. a Various compounds demonstrated a
dose-dependent inhibition of RVFV NP assembly in the plate assay. b Similar compounds were effective against LASV NP assembly. c The selected
“hit” compounds were potent in the live virus assay for both RVFV and LASV. d Exposure of the compounds to HEK-293 cells indicates no toxicity
in their active concentration
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Methods
Materials were purchased from Sigma Chemicals Co.
or Thermo-Fisher unless otherwise noted. Affinity
purified antibodies to RVFV NP are available from
http://www.prosetta.com.
Cell-free transcription, translation, and chase experiments
The cell-free transcription was performed and adapted
to linked translation as previously described, with the
following adjustments [10, 11, 22]. The coding region
of the RVFV NP was engineered behind the SP6 bac-
teriophage promoter and the Xenopus globin 5′ UTR.
The PCR product of the RVFV NP was transcribed
in vitro to generate mRNA encoding each full-length
protein. The translations were carried out in the WG
CFPS system supplemented with either [35S] methio-
nine at 0.2 μM (ICN Biochemicals) or with all 20
nonradiolabeled amino acids, as previously indicated
[11, 22, 26]. The translations were performed as pre-
viously described [21, 26] at the various temperatures
and incubation times as indicated for each experi-
ment. The WG extracts were used at 20 % of the
total translation volume unless otherwise indicated.
Additional components included 0.8 μM MgOAc,
80 μM KOAc, unlabeled cysteine and methionine to a
final concentration of 25 μM. This was found to be
optimal for RVFV NP core translation and assembly.
The translation reaction mixture contained 15.6 mM
ATP, 15.6 mM GTP, and 31.3 mM CTP diluted in
water. A “column buffer” (4 mM HEPES at pH 7.8
with KOH, 0.8 mM KOAc, 0.8 μM MgOAc) was used
as a substitute for the dilution of T2 when loaded
onto the gradient or when the transcripts were di-
luted. A ”chase buffer “(4 mM HEPES, pH 7.6 and
0.1 mM EDTA, pH 7) was used as a mock chase ma-
terial instead of the WG extract.
a 
c b
Fig. 5 Small molecules selected by the plate assay inhibit HOFS formation. a The CFPS of RVFV NP was performed in the presence of compounds
6051, 7007 or 1 % DMSO and loaded onto sucrose gradients. Sucrose fraction 1 was loaded onto glycerol gradients. b Chemical structures of
selected potent compounds
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Sucrose and glycerol gradients
The translation products (30 μl unless otherwise indi-
cated) were loaded onto the sucrose gradients, in 1 % w/v
Triton X-100, 50 mM, 4 mM HEPES at pH 7.6,
100 mM KOAc, and 5 mM MgOAc. The samples
were adjusted to 150 μl with the column buffer. The
sucrose step gradients (2 ml) were poured by layering
60 % to 10 % (from bottom to top) sucrose stock so-
lutions containing the same Triton and salt concen-
tration as the sample; this was followed by 1 h of
diffusion at room temperature. The gradients were
then cooled to 4 °C before the samples were loaded
and centrifuged in a TL-100 Beckman ultracentrifuge
(Beckman Coulter Inc., Carlsbad, CA) using a TLS55
swinging bucket rotor at 50,000 rpm for 55 min at
4 °C. After centrifugation, 200 μl fractions were re-
moved from the top of the meniscus with a pipette,
and the pellet was resuspended in 200 μl of 10 % su-
crose stock solution. A 20 μl aliquot of each fraction
was adjusted with sodium dodecyl sulfate (SDS)-con-
taining loading buffer (10 % glycerol, 2 % SDS,
50 mM Tris at pH 6.8, 0.001 % bromophenol blue,
50 mM DTT), analyzed on a 12 or 15 % acrylamide-
SDS gel prepared using Tris-glycine buffer at pH 8.8 as
previously reported [12] and visualized by autoradiography.
Specific bands were quantified densitometrically with Ima-
geJ software. As a loading control, unlabeled proteins were
visualized by Coomassie staining of the gels.
Then, 2-ml glycerol linear gradients, from 10 % to
30 % in column buffer, were poured using a gradient
former and cooled to 4 °C. A 75 μl aliquot of fraction 1
of the previously run sucrose gradients were adjusted to
150 μl in column buffer with a final concentration of
1 % Triton X-100, loaded onto the gradient and centri-
fuged at 55,000 rpm for 16 h at 4 °C with the same rotor
used for the sucrose gradients. After centrifugation,
100 μl fractions were removed sequentially from the top
of the tube as above. The samples were centrifuged and
prepared for SDS-PAGE as described above.
Protease treatment
RVFV NP translation was performed by CFPS at 37 °C
for 1 h in the presence of [35S] methionine at 0.2 μM,
analyzed by sucrose gradients and 75 μl of fraction 1 of
the sucrose gradients was analyzed by glycerol gradi-
ents. Twenty microliter aliquots were taken from the
glycerol gradient fractions of interest (F8, F9, and F22)
and incubated with either buffer or proteinase K at
various dilutions (final concentrations of 10, 1, and
0.1 ng/ml). Protease treatment of the samples was per-
formed at 37 °C for 2 h and terminated by the addition
of PMSF and heating to 100 °C for 2 min in SDS load-
ing buffer. Samples were the separated on a 12 % or
15 % SDS-PAGE gel. The RVFV NP was visualized by
autoradiography and quantified as previously described.
Cell culture expression and Western blot analysis of
RVFV NP
An 80 % confluent monolayer of HEK 293 cells was
transfected using Transfast (Promega, Madison, WI) for
Fig. 6 Cyclic peptides representing RVFV N- and C-terminus inhibit the assembly of IOAS into HOFS. Cyclic peptides, representing different
residues within RVFV NP, at various concentrations (H, High = 20 μM; M, Medium = 2 μM; L, Low = 0.2 μM) were diluted in 1 % DMSO and
incubated in the CFPS assay. To control for the effect of the cyclic peptides on protein synthesis, eGFP was cotranslated in the presence
of the various compounds
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non-radioactive expression of RVFV NP encoding plas-
mid in 10 cm dishes at 37 °C with 5 % CO2. Cells were
lysed 48 h after transfection in 300 μl of lysis buffer (The
samples were adjusted to 100 μl with 5 % v/v Triton
X-100, 5 M Tris at pH 8, and 0.44 g NaCl) and
protein concentration was quantified by absorbance at
280 nm. Expression of RVFV NP was confirmed by
analyzing 100 μg of lysates/well on SDS-PAGE
followed by immune blotting with RVFV NP specific
antibodies. A 2 μl of total RVFV NP CFPS sample
was used as a positive control for the Western blot
analysis. The primary antibody was a rabbit polyclonal
antibody diluted 1:1000 and the secondary antibody
was an anti-rabbit alkaline phosphate monoclonal
antibody diluted 1:5000 (Sigma Chemical Co, St. Louis,
MO). All antibodies were diluted in 2.5 % dry milk in
TBST 0.05 %. 1 mg of total protein from the cell lysate
was analyzed on a sucrose gradient and 137.5 μl of frac-
tion 1 from the sucrose gradient was analyzed on a gly-
cerol gradient as described above. In order to detect the
RVFV NP expression in glycerol gradients by immuno-
blotting, blots were incubated overnight with primary and
secondary antibody.
Immunoprecipitation and purification of the antibodies
The specific fractions from the sucrose and glycerol
gradients (60 μl each) were incubated with 1 μl of
1 mg/ml RVFV NP antibody, 250 μl of 1 % Triton-
containing column buffer (Triton buffer), and 20 μl of
either protein G- or A-linked beads (Bio-Rad) at 4 °C
on a rotating wheel for 24 h. The beads were washed
three times with 1 ml of 1 % Triton buffer, and this
was followed by a final wash with 1 ml detergent-free
salt solution (0.1 M Tris at pH 8 and 0.1 M NaCl). A
2 % SDS-containing loading buffer (with or without
DTT) was added to each sample, and samples were
then heated for 2 min at 100 °C and then separated
on a 12 or 15 % SDS-PAGE gel. The RVFV NP was
visualized by autoradiography and quantified as previ-
ously described. The polyclonal antibodies were raised
against an RVFV NP peptide in rabbits, and the
RVFV NP monoclonal antibodies were generated at
USAMRIID. The antibody generation, purification and
labeling were performed as previously described [27].
ELISA
The plate screens were performed as previously de-
scribed with the following modifications [12]: The CFPS
consisted of WG extract, RVFV NP mRNA, eGFP
mRNA, amino acids and an energy-regenerating system.
The CFPS were performed first under conditions that
did not generate the oligomerization of the NP (26 °C
for 20 min) but created enough NP to oligomerize under
the right conditions (shift to 37 °C for a longer
incubation time). The CFPS translation products were
transferred to capture plates previously coated with a
monoclonal anti-RVFV NP affinity-purified antibody.
The fluorescently labeled anti-RVFV NP monoclonal
antibody stained with a secondary biotinylated affinity-
purified antibody was added, washed, detected by
NeutrAvidin HRP, washed again and incubated with
fluorescein HRP substrate Quanta Blue for 1 h. The
fluorescence signal was measured at 330/425 nm (ex-
citation/emission) Reagents were obtained from Pierce
Research. RVFV NP bound to the plate was then de-
tected by the same antibody only if more than a
monomer of RVFV NP was present. Drugs blocking
this oligomerization inhibit the fluorescence. To ex-
clude false positive compounds that inhibit transcrip-
tion or translation, eGFP was cotranslated with RVFV
NP, and the extent of eGFP fluorescence was moni-
tored before the CFPS product material was trans-
ferred to the capture plate.
Image analysis and quantification
Autoradiographs and immunoblots were quantified
using Epson Silver Ai scanner, Adobe Photoshop, and
Image J software (Image J). Integrated densities of
each band were normalized against background to ob-
tain quantitative values for graphs and charts using
Microsoft Excel.
Virus yield reduction assays
The effectiveness of the compounds was evaluated by
virus yield reduction assay using Vero E-6 cells
(American Type Culture Collection, Manassas, VA).
The cells were maintained in Modified Eagle’s media
(MEM) with 10 % fetal bovine serum (FBS), and 1X
GlutaMax (Invitrogen, Carlsbad, CA). RVFV and
LASV were evaluated using 90 % confluent cells in 6-
well plates. Medium was removed from cells which
were infected at an MOI of 0.1 in 200 μl of medium
(MEM) containing 5 % FBS and no antibiotics that
contained various concentration of compound. Plates
were incubated 1 h at 37 °C/5 % CO2 with rocking
every 15 min. Media containing virus was removed
and plates were washed 3X with media or phosphate
buffered saline (PBS; Invitrogen). After washing,
media that contained various concentrations of com-
pound was added and plates were incubated at 37 °C/
5 % CO2. Supernatant was collected on day 1 and 2
post-infection (PI) for viral titer determination by
plaque assay.
Plaque assay
Plaque assays for RVFV and LASV used 90–100 % con-
fluent Vero cells in 12-well plates. Samples for titration
were serially diluted 10-fold and 100 μL was added to
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each well. Plates were incubated for 1 h at 37 °C with
rocking every 15 min. A primary overlay containing 1X
EBME, 5 % FBS, and 0.5 % agarose was added to each
well. Plates were incubated at 37 °C/5 % CO2 for 3
(RVFV) or 4 (LASV) days followed by a secondary over-
lay, which was the same as the primary overlay with the
addition of 5 % neutral red. Plaques were counted on
day 4 (RVFV) or 5 (LASV) PI.
Toxicity of compounds in vitro
The toxicity of the compounds was evaluated in 96-
well HEK cells for 24 h. The same concentration of
compound used for the yield reduction assay was added
to the cells and the toxicity was evaluated using Prome-
ga’s CellTiter-Glo Luminescent Cell Viability Assay
(Madison, WI) according to manufacturer’s recommen-
dations. Briefly, compounds were added to the plate in
triplicate and incubated at 37 °C/5 % CO2. Following
the appropriate incubation period, media containing
test compound was removed and replaced with fresh
media without compound and the cell titer glo sub-
strate. The plates were rocked for 2 min followed by
10 min incubation at room temperature to allow the
signal to stabilize. Plates were read on a luminometer
(SpectraMax M5, Molecular Devices, Sunnyvale, CA) at
an integration time of 500 ms.
Densitometric quantification and statistics
Quantification of radioactive material on SDS-PAGE
samples exposed to X-Ray films was determined using
the NIH image J software. The data represents the
average and standard deviation of three independent
experiments for each condition. Bonferroni’s multiple
comparison test analysis, using Prism 6 software, was
used for comparisons between multiple conditions.
Differences between conditions were considered to be
statistically significant when p < 0.05.
Reviewers’ comments
Reviewers’ report 1: Professor Jeffry Skolnick, Buffalo
center of excellence in bioinformatics, USA
This paper describes a very clever in vitro system that
can be used to characterize virus capsid assembly and
which can do so at high throughput. Application to
Rift Valley fever virus shows that the assembly system
works. Moreover, it was successfully used to identify
some related small molecules, Overall this is a very
nice piece of work.
Overall this is a nice piece of work which has broad
ramifications with tremendous potential to characterize
virus capsid formation as well as assist in the identification
of novel antivirals. I do have some minor recommenda-
tions. 1. Discuss how the 10,000 molecules in the screen-
ing library was selected and how many were known to
have antiviral activity for other viruses. 2. What % of mol-
ecules screened had any antiviral activity? Were any novel
antivirals identified? 3. Can you target the intermediately
ordered structures by a more directed approach? 4. Dis-
cuss the limitations of your cell free screening system.
Authors’ response
1. The 10,000 compounds represent a selected portion
of a larger library of approximately 90,000 drug-like
compounds in the Prosetta compound collection.
2. They have not been systematically screened for
other viruses at this point, but clearly have varying
degrees of antiviral activity differing from viral
family to viral family. Less than 0.05 % of screened
compounds were scored as hits, on average, of the
viruses screened. A substantial percentage (up to
75 %) of hits were active against infectious virus in
mammalian cell culture, varying from viral family
to viral family. A number of these were novel
anti-viral small molecules. We have selected analogs
of one chemotype, the phenothiazine derivatives to
illustrate the points made in this paper.
3. We have not attempted a more directed approach to
targeting assembly intermediates. We believe this
would be possible but was beyond the scope of the
present study.
4. Our cell-free screening method, has both strengths
and limitations. The obvious strength is that it allows
targeting of a host-directed catalytic pathway that has
not been previously accessible. The limitations
however are several. First, while a number of targets
are clearly shared between plant and animal extracts,
some may not be, and therefore will be missed.
Second, the degree of divergence from target to target
between plant and animal extracts is not clear. As a
result it is possible that structure-activity relationship
(SAR) will not be identical between the plant and
animal targets, and optimization against the one may
diverge from the optimum for the other. A counter to
this point is that, in addition to targeting host factors,
the present screen may also pick up direct anti-viral
targets, although those are likely to be less potent as
they lack the catalytic power of a host enzyme. Finally,
as established the current screen only allows moderate
throughput of compounds. As a result, thousands, but
not hundreds of thousands, of compounds can be
screened in a reasonable time.
Reviewers’ report 2: Professor Noah Isakov, Ben Gurion
University of the Negev, Israel
The purpose of this paper is to utilize a cell-free
in vitro transcription-translation system for the
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synthesis of Rift Valley fever virus (RVFV) nucleopro-
tein capsids (NP), characterize the in vitro generated
assembled products, and test whether the extent of the
in vitro assembled RVFV-NP can serve as means for
the screening and identification of potential anti-RVFV
drugs. Optimization of the in vitro transcription-
translation system and sequential separation of the
translated RVFV-NP products on sucrose and glycerol
gradients yielded two distinct fractions, which are sug-
gested to represent highly ordered filamentous struc-
tures (HOFS) versus intermediately ordered assembled
structures (IOAS) of the RVFV-NP. Further analyses of
assembly-defective RVFV-NP mutants, as well as ‘chase’
experiments with S35-labeled RVFV-NP substantiated
the assumption that fractions containing IOAS and
HOFS represent intermediates versus fully assembled
NP structures. Finally, using a HOFS-NP-specific mAb,
the authors developed an ELISA-based throughput sys-
tem for the screening of anti-RVFV drugs, thereby
overcoming the requirement for a biocontainment facil-
ity. An applicability of this model for anti-Lassa virus
drug screening is also demonstrated.
This is an interesting, well-executed study, which I am
happy to endorse. Minor comments:
1. The authors should compare the findings in Figs 4 &
5 and discuss the reasons for the dramatic differences
in the inhibitory effects of the drugs in the ELISA
(>1000-fold inhibition) versus those observed
following the sucrose/glycerol separation (~2-fold).
2. Page 10: Actual data of drug toxicity tested in HEK
cells (Fig. 4d) is missing from Fig. 3.
3. Page 10, 3rd paragraph: The structure of the
compounds is illustrated in Fig. 5c (and not Fig. 5b,
as indicated).
4. Page 10, 3rd paragraph, line 4: “exposed for 24 h ‘to’
(instead of ‘with’).
5. Additional file 9: figure S9: Correct ‘Meidia’ to
‘Media’.
Authors’ response
1. One possibility that might explain this difference is
that in the glycerol fractions contain different
intermediates and the monoclonal antibody used in
the ELISA recognizes only a very specific
conformation that is specifically inhibited by the
compounds. This is a very interesting observation by
the reviewer but was beyond the scope of the
present study.
2. We thank the reviewer and we added the missing
figure. A new version of Fig. 4 was created and
resubmitted.
3. The requested modification was made.
4. The requested modification was made.
5. A new version of Additional file 9: figure S9 was
created and resubmitted.
We thank the reviewers for improving the initial
manuscript by sharing their professional feedback. We
would like to extend our gratitude to the editor and the
unique open review process at the Biology Direct journal
that facilitates such quality of review.
Additional files
Additional file 1: figure S1. RVFV NP characterization using an
immunoprecipitation assay and proteinase K digestion (PK). Upper
drawing: schematic illustration of the glycerol gradient profiles, which
consist of two distinct sedimentation peaks representing putative
assembly intermediates (peak I) and highly ordered assembled particles
(peak II). (A) SDS-PAGE analysis of the radioactively labeled CFPS products.
(B) Glycerol gradient fractions of the immunoprecipitated material
resulting from a mixture of peaks I and II. (C) Glycerol gradient fractions
of the immunoprecipitated material resulting from peak I. (D) Glycerol
gradient fractions of the immunoprecipitated material resulting from
peak II. The data strongly suggest that peak II represents native-like fully
assembled capsids, whereas peak I represents assembly intermediates. (E)
Radioactively labeled RVFV NP was translated for 1 h at 26 °C and equal
amounts of RVFV NP from the middle fractions 8 and 9 (lanes 4 and 5)
and the bottom fraction 22 (lane 6) from the glycerol gradients were
loaded onto an SDS-PAGE gel and stained with Coomassie brilliant blue.
(F) The same concentration of radioactively labeled RVFV NP from each
fraction (lanes 1 and 2 represent fractions 8 and 9 from the glycerol
gradients, and lane 3 represents fraction 22) was exposed to 100 μg/ml
PK or (G) 250 μg/ml PK. As a negative control to the PK reaction, DDW
was added to the same final volume as the PK. As a positive control for
PK activity, 4 μg of BSA was added to 20 μl of each reaction. The PK
digestion assay was performed for 2 h at 37 °C. The input of the RVFV NP
was normalized before PK digestion. BSA was detected using Coomassie
staining (Additional file 1: figure S1 e, f and g lower panel). (PDF 3164 kb)
Additional file 2: figure S2. Glycerol gradient fractions of CFPS and
293 HEK cells expressing RVFV NPs WT and mutants. (A) Radioactively
labeled RVFV NRP was translated in 26 °C for an hour and run onto
a sucrose gradient. First top fraction (F1) or 2nd top fraction (F2)
were rerun onto a glycerol gradient. Samples were ultra-centrifuged
for 16 h at 55Kg. (B) Shorter (6 h) and longer (16 h) ultracentrifugation of
glycerol gradients were compared side by side. (C) HEK 293 cells were
transfected with wild type RVFV NRP. Cell lysates of transfected cells were
loaded onto sucrose gradient, and thereafter, top fraction of sucrose
gradient was re-loaded onto glycerol gradients. All fractions of both
gradients were loaded onto SDS-PAGE gels following western blot
analysis using a monoclonal antibody against RVFV NRP. RVFV NRP
translated by CFPS was used on each of these gels as a positive
control (PC). (D) Radioactively labeled RVFV NRP was translated in
26 °C for an hour and run onto a sucrose gradient. First top fraction
was rerun onto a glycerol gradient. Samples were ultra-centrifuged
for 16 h at 55Kg. Glycerol gradients of Full length wild-type NP;
(E) N-terminal deleted NP mutant; (F) C-terminal deleted mutant.
Note the scarcity of the high order assembly capsids in the mutant
gradients (fractions 20–23). (PDF 1534 kb)
Additional file 3: figure S3. Transcript concentration in the in vitro
translation reaction affects RVFV NP distribution on the sucrose gradients.
Note that the amplitude of peak II (see Additional file 3: figure S3),
representing high-order assembly structures, required higher amounts
of RNA. The reactions were carried out at 26 °C, conditions that favor
the accumulation of intermediates; accordingly, a substantial amount of
the material was always found in peak I, representing the assembly
intermediates. See also Additional file 4: figure S4 for optimization of the
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conditions that enable a clear distinction between the peaks representing
the partially and highly ordered assembled structures. (PDF 57 kb)
Additional file 4: figure S4. Glycerol gradient fractions of CFPS-generated
RVFV NPs obtained by increasing the duration and temperature of
the translation reaction. A) Glycerol gradient sedimentation of the
reactions carried out at 26 °C for increasing durations of translation.
B) Glycerol gradient sedimentation of the reactions carried out at
37 °C for increasing durations of translation. The significance of the
colors of the various curves is detailed in the legends on the right.
Equal amounts of the radioactive products were loaded onto the
gradients in all cases, and 10 % of the transcripts were used in the
translation step. (PDF 147 kb)
Additional file 5: figure S5. Glycerol gradient profiles of various
CFPS-generated NPs obtained by translation/transcription of different
virus families. Nucleoproteins (NP) of Hepatitis C virus (HCV), RVFV,
Hantaan virus (HNTN) and Lassa fever virus (LASV) were translated for 1 h
at 26 °C to enable the formation of both intermediate and highly ordered
assembly structures. HCV NP has a compact capsid structure, whereas
RVFV, HNTN and LASV are flexible filamentous-capsid viruses. The
colors of the profiles of the various viruses are indicated on the right
legend. (PDF 76 kb)
Additional file 6: figure S6. Full conversion of the intermediate
capsid structures into highly ordered capsids by nonradioactive
CFPS-products. Glycerol-gradient fractionation profiles of the
radioactive material generated by CFPS under conditions favoring
intermediate-assembly structures and “chased” by the addition of
intermediate-assembly structures of nonradioactive products. As indicated:
dark blue, “mock” chase experiment (addition of buffer only); green, “chase”
experiment (addition of nonradioactive intermediate structures). The chase
was performed for 45 min at 37 °C. (PDF 53 kb)
Additional file 7: figure S7. Conversion of the IOAS into IHOS by
nonradioactive CFPS-products is not affected by Apyrase. Glycerol-gradient
fractionation profiles of the radioactive material generated in CFPs under
conditions favoring intermediate-assembly structures and “chased” by the
addition of nonradioactive products for 120 min and carried out in the
presence or absence of the ATP inhibitor Apyrase (final concentration of 0.5
U/μl in the cell-free reaction mixture) at 37 °C. Note that in all cases, in
addition to the chase at 26 °°C, the material in peak I (intermediate
assembly structures) was converted to the highly ordered assembly
structures (Peak II), indicating that the process of RVFV NP assembly is
indeed independent of energy but is temperature dependent. (PDF 88 kb)
Additional file 8: figure S8. Specificity of various antibodies against
RVFV NP tested by immunoprecipitation of the radiolabeled CFPS
RVFV NP. (A) In all lanes, immunoprecipitated CFPS RVFV NPs were
loaded, with the exception of lane 4, which represents the total
material before immunoprecipitation (positive control), and lane 11,
which represents the CFPS product of the Venezuelan Equine Encephalitis
Virus NP (negative control). The following antibodies were tested: Lane 1,
Monoclonal anti-native RVFV (see Additional file 1: figure S1); Lanes 2, 7, 8
and 9, four different rabbit polyclonal anti-RVFV antibodies; Lanes 3, 5 and 6,
three different pig polyclonal anti-RVFV antibodies. The monoclonal antibody
used for the immunoprecipitation reaction analyzed in lane 1, was also used
in the high-throughput system (see text). (B) Optimization of the plate assay
was performed comparing the purification of the capture Ab by ammonium
persulfate (A-C, G-N) with the protein G purification (D-F, O, P), in 1:250
dilution (A-D, F-N, P) or 1:500 (E, O), whereas the biotinylated detection Ab
was diluted to 1:126 (A-G, K-P) or to 1:250 (H). (PDF 113 kb)
Additional file 9: figure S9. Cell fractionation indicates that the
compounds access the nucleus. The most potent compounds were
exposed to HEK cells at a concentration of 1 μM for 24 h, after which the
nucleus was separated from the cytoplasm. The concentration of these
two blue compounds could be observed by the relative higher intensity
in the nucleus compared to that in the cytoplasm. (PDF 3721 kb)
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